Sexually Transmitted Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major sexually transmitted disease markets reached a value of US$ 40.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 95.0 Billion by 2034, exhibiting a growth rate (CAGR) of 8.01% during 2024-2034.
The sexually transmitted diseases market has been comprehensively analyzed in IMARC's new report titled "Sexually Transmitted Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sexually transmitted diseases (STDs) refer to infections that are transmitted through sexual activity, including vaginal, anal, or oral sex. These can manifest with a wide range of symptoms, although many conditions may not cause any noticeable signs initially. Some of the common indications are genital itching, pain during urination, unusual discharge from the vagina or penis, sores, bumps, or rashes in the genital area, painful sexual intercourse, swelling or redness of the genitals, etc. Additionally, many STDs can cause flu-like symptoms, such as fever, fatigue, body aches, etc. The diagnosis of sexually transmitted diseases involves various methods to determine the presence of an infection. Healthcare professionals may use a combination of medical history assessment, physical examination, laboratory investigations, and imaging studies. A physical exam may involve inspecting the genital area for visible signs of infection. Furthermore, laboratory tests are crucial for a definitive diagnosis and may include blood, urine, and fluid samples from affected areas. In some cases, several imaging studies, like ultrasounds and X-rays, may be necessary to assess the extent of infection or complications.
The increasing cases of unprotected vaginal, anal, or oral sex with an infected partner are primarily driving the sexually transmitted diseases market. In addition to this, the rising prevalence of disease transmission through non-sexual routes, such as blood transfusions, sharing contaminated needles, from mother to child during pregnancy, childbirth, breastfeeding, etc., is acting as another significant growth-inducing factor. Moreover, the widespread demand for antiviral medications, like acyclovir, valacyclovir, famciclovir, etc., to manage outbreaks, reduce symptoms, and lower the risk of transmission is further bolstering the market growth. Apart from this, the inflating application of long-acting injectable antiretrovirals, since they provide sustained drug levels in the body while improving adherence and simplifying treatment regimens, is also creating a positive outlook for the market. Additionally, the ongoing advancements in molecular diagnostics, including the introduction of transcription-mediated amplification (TMA) and loop-mediated isothermal amplification (LAMP), which can detect and amplify the genetic material (DNA or RNA) of pathogens, thereby providing highly sensitive and specific results, are expected to drive the sexually transmitted diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the sexually transmitted diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for sexually transmitted diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sexually transmitted diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the sexually transmitted diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the sexually transmitted diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current sexually transmitted diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the sexually transmitted diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the sexually transmitted diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the sexually transmitted diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by type across the seven major markets?
How many patients are diagnosed (2018-2034) with sexually transmitted diseases across the seven major markets?
What is the size of the sexually transmitted diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of sexually transmitted diseases?
What will be the growth rate of patients across the seven major markets?
Sexually Transmitted Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for sexually transmitted diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sexually transmitted diseases market?
What are the key regulatory events related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by status related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by phase related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by route of administration related to the sexually transmitted diseases market?
The sexually transmitted diseases market has been comprehensively analyzed in IMARC's new report titled "Sexually Transmitted Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sexually transmitted diseases (STDs) refer to infections that are transmitted through sexual activity, including vaginal, anal, or oral sex. These can manifest with a wide range of symptoms, although many conditions may not cause any noticeable signs initially. Some of the common indications are genital itching, pain during urination, unusual discharge from the vagina or penis, sores, bumps, or rashes in the genital area, painful sexual intercourse, swelling or redness of the genitals, etc. Additionally, many STDs can cause flu-like symptoms, such as fever, fatigue, body aches, etc. The diagnosis of sexually transmitted diseases involves various methods to determine the presence of an infection. Healthcare professionals may use a combination of medical history assessment, physical examination, laboratory investigations, and imaging studies. A physical exam may involve inspecting the genital area for visible signs of infection. Furthermore, laboratory tests are crucial for a definitive diagnosis and may include blood, urine, and fluid samples from affected areas. In some cases, several imaging studies, like ultrasounds and X-rays, may be necessary to assess the extent of infection or complications.
The increasing cases of unprotected vaginal, anal, or oral sex with an infected partner are primarily driving the sexually transmitted diseases market. In addition to this, the rising prevalence of disease transmission through non-sexual routes, such as blood transfusions, sharing contaminated needles, from mother to child during pregnancy, childbirth, breastfeeding, etc., is acting as another significant growth-inducing factor. Moreover, the widespread demand for antiviral medications, like acyclovir, valacyclovir, famciclovir, etc., to manage outbreaks, reduce symptoms, and lower the risk of transmission is further bolstering the market growth. Apart from this, the inflating application of long-acting injectable antiretrovirals, since they provide sustained drug levels in the body while improving adherence and simplifying treatment regimens, is also creating a positive outlook for the market. Additionally, the ongoing advancements in molecular diagnostics, including the introduction of transcription-mediated amplification (TMA) and loop-mediated isothermal amplification (LAMP), which can detect and amplify the genetic material (DNA or RNA) of pathogens, thereby providing highly sensitive and specific results, are expected to drive the sexually transmitted diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the sexually transmitted diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for sexually transmitted diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sexually transmitted diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the sexually transmitted diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the sexually transmitted diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current sexually transmitted diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the sexually transmitted diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the sexually transmitted diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the sexually transmitted diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of sexually transmitted diseases by type across the seven major markets?
How many patients are diagnosed (2018-2034) with sexually transmitted diseases across the seven major markets?
What is the size of the sexually transmitted diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of sexually transmitted diseases?
What will be the growth rate of patients across the seven major markets?
Sexually Transmitted Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for sexually transmitted diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sexually transmitted diseases market?
What are the key regulatory events related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by status related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by phase related to the sexually transmitted diseases market?
What is the structure of clinical trial landscape by route of administration related to the sexually transmitted diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEXUALLY TRANSMITTED DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEXUALLY TRANSMITTED DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEXUALLY TRANSMITTED DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SEXUALLY TRANSMITTED DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEXUALLY TRANSMITTED DISEASES - UNMET NEEDS
10 SEXUALLY TRANSMITTED DISEASES - KEY ENDPOINTS OF TREATMENT
11 SEXUALLY TRANSMITTED DISEASES - MARKETED PRODUCTS
11.1 List of Sexually Transmitted Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Zyclara (Imiquimod) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Solosec (Secnidazole) - Lupin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tindamax (Tinidazole) - Mission Pharmacal
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Ziagen (Abacavir) - GSK
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Emtriva (Emtricitabine) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEXUALLY TRANSMITTED DISEASES - PIPELINE DRUGS
12.1 List of Sexually Transmitted Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 GSK 4348413A - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VP 102 - Verrica Pharamceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Cabotegravir - ViiV Healthcare
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lenacapavir - Gilead Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Zinlirvimab+Teropavimab+Zinlirvimab - Gilead Sciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEXUALLY TRANSMITTED DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEXUALLY TRANSMITTED DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEXUALLY TRANSMITTED DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Sexually Transmitted Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Sexually Transmitted Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Sexually Transmitted Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Sexually Transmitted Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Sexually Transmitted Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Sexually Transmitted Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Sexually Transmitted Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Sexually Transmitted Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Sexually Transmitted Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Sexually Transmitted Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Sexually Transmitted Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Sexually Transmitted Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Sexually Transmitted Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Sexually Transmitted Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Sexually Transmitted Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Sexually Transmitted Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
16 SEXUALLY TRANSMITTED DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEXUALLY TRANSMITTED DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEXUALLY TRANSMITTED DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEXUALLY TRANSMITTED DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEXUALLY TRANSMITTED DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEXUALLY TRANSMITTED DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SEXUALLY TRANSMITTED DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEXUALLY TRANSMITTED DISEASES - UNMET NEEDS
10 SEXUALLY TRANSMITTED DISEASES - KEY ENDPOINTS OF TREATMENT
11 SEXUALLY TRANSMITTED DISEASES - MARKETED PRODUCTS
11.1 List of Sexually Transmitted Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Zyclara (Imiquimod) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Solosec (Secnidazole) - Lupin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tindamax (Tinidazole) - Mission Pharmacal
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Ziagen (Abacavir) - GSK
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Emtriva (Emtricitabine) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEXUALLY TRANSMITTED DISEASES - PIPELINE DRUGS
12.1 List of Sexually Transmitted Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 GSK 4348413A - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VP 102 - Verrica Pharamceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Cabotegravir - ViiV Healthcare
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lenacapavir - Gilead Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Zinlirvimab+Teropavimab+Zinlirvimab - Gilead Sciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEXUALLY TRANSMITTED DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEXUALLY TRANSMITTED DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEXUALLY TRANSMITTED DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Sexually Transmitted Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Sexually Transmitted Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Sexually Transmitted Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Sexually Transmitted Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Sexually Transmitted Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Sexually Transmitted Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Sexually Transmitted Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Sexually Transmitted Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Sexually Transmitted Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Sexually Transmitted Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Sexually Transmitted Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Sexually Transmitted Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Sexually Transmitted Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Sexually Transmitted Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Sexually Transmitted Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Sexually Transmitted Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Sexually Transmitted Diseases - Access and Reimbursement Overview
16 SEXUALLY TRANSMITTED DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEXUALLY TRANSMITTED DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEXUALLY TRANSMITTED DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
